Hester Biosciences Ltd

Stage 3 · Topping · week 3

As of 16 Oct 2026, Hester Biosciences is in Stage 3 — topping, where an uptrend loses steam, in week 3 (since 30 Sep 2026). It closed at ₹2,237, 12.1% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. More about the company

₹2,236.5

+1.83% today

₹1,903 Cr · Small cap

Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dBiotechnology 22.2%-11.1 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is HESTERBIO early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months ₹1,999 · 6 months

Loading price chart…

vs 52W High

-12.1%

₹1,259.1 lo₹2,545 hi

12.1% below 52W high — weakening from peak

Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.

Stage Maturity

Week 3

1w13w26w

Week 3 — early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

18.3%

200 DMA: ₹1,890.7 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.49x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.

Trend Health

↓

MA20 rolling over · -3.1% vs MA50 -4.4%

Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.

+1.3%

-8.6%

+50.8%

YTD

+41.3%

+26.8%

Sector

Health Care

↓ Peaking

Stage 2%

40.0%

20d Δ

-7.4pp

1M return

-3.8%

3M return

-1.0%

Sector Stage-2 % · last 20 days

Sector has 66 Stage 2 leaders. See Health Care Stage 2 →

Industry

Biotechnology

↓ Peaking

Stage 2%

22.2%

20d Δ

-11.1pp

1M return

-7.7%

3M return

-6.9%

Industry Stage-2 % · last 20 days

Industry has 2 Stage 2 leaders. See Biotechnology Stage 2 →

Stage Cycle Timeline2023-07-20 → 2026-10-16

S4 29w

S2 18w

S4 14w

S1 16w

S4 23w

S2 16w

2023-07-202026-10-16

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 3w → S1 8w → S4 29w → S1 4w → S2 18w → S3 9w → S2 8w → S3 2w → S4 14w → S1 16w → S2 5w → S3 5w → S4 23w → S1 5w → S2 16w → S3 2w current

Total tracked: 168 weeks across 16 stage runs.

Scan Membership

Prop Scan

Latest: 2026-09-04

Pullback Hunter

Latest: 2026-08-21

60 appearances in last 60 days. First seen: 2026-07-10.

Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.

Recent Stage Timeline

2026-10-16S3

Wk 3 · Vol 0.49x

2026-10-15S3

Wk 3 · Vol 0.95x

2026-10-14S3

Wk 2 · Vol 0.35x

2026-10-13S3

Wk 2 · Vol 0.23x

2026-10-12S3

Wk 2 · Vol 0.18x

2026-10-09S3

Wk 2 · Vol 0.17x

2026-10-08S3

Wk 2 · Vol 0.17x

2026-10-07S3

Wk 1 · Vol 0.12x

2026-10-06S3

Wk 1 · Vol 0.27x

2026-10-05S3

Wk 1 · Vol 0.17x

2026-10-01S3

Wk 1 · Vol 0.17x

2026-09-30S32→3

Wk 1 · Vol 0.15x

Sector Peers — Stage 2All →

BAFNAPH

wk 19 · 0.0% from hi

8.6

KILITCH

wk 3 · -11.6% from hi

8.4

LAURUSLABS

wk 26 · -0.4% from hi

7.8

KOPRAN

wk 20 · -6.8% from hi

7.4

ZIMLAB

wk 23 · -5.2% from hi

6.9

Moving averages & range

50 DMA

₹2,271.4

200 DMA

₹1,890.7

52W High

₹2,545

52W Low

₹1,259.1

5D Low

₹2,095.6

Resistance levels (recent highs)

20d High

₹2,241.8

60d High

₹2,528.4

120d High

₹2,545

250d High

₹2,545

Next resistance

+0.2%

to 20d High

Ask the Market AI about HESTERBIOAsk →

P/E (TTM)

29.5

Forward —

Earnings Growth (YoY)

+968.7%

Revenue +38.2%

ROE

+16.6%

Profit margin +16.7%

Dividend Yield

0.32%

P/B 4.7

About this companyHealth Care· Biotechnology

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella abortus, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming aids, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, vitamins, minerals and specialty feed supplements, and various formulations for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides sero-profiling kits, diagnostic labs for poultry flocks, and mastitis control programs for cattle; and manufactures and trades in goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.